Voluntis expanding their global pharma collaborations

Eisai partnering with Voluntis to develop digital therapeutics for oncology patients

By leveraging Voluntis’ Theraxium technology platform, the two companies will collaborate on designing and developing innovative digital therapeutics (DTx) to support patients treated for cancer. In addition to their partnership in oncology, the companies announced a strategic investment from Eisai in Voluntis and plan to explore other opportunities of collaboration to develop, evaluate and commercialize digital therapeutics based on the Theraxium platform in the field of neurology.

Link to their press release